The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice.
BACKGROUND
Chronic transfusion therapy causes a progressive iron overload that damages many organs including the heart. Recent evidence suggests that L-type calcium channels play an important role in iron uptake by cardiomyocytes under conditions of iron overload. Given that beta-adrenergic stimulation significantly enhances L-type calcium current, we hypothesised that beta-adrenergic blocking drugs could reduce the deleterious effects of iron overload on the heart.


METHODS
Iron overload was generated by intraperitoneal injections of iron dextran (1g/kg) administered once a week for 8 weeks in male C57bl/6 mice, while propranolol was administered in drinking water at the dose of 40 mg/kg/day. Cardiac function and ventricular remodelling were evaluated by echocardiography and histological methods.


RESULTS
As compared to placebo, iron injection caused cardiac iron deposition. Surprisingly, despite iron overload, myocardial function and ventricular geometry in the iron-treated mice resulted unchanged as compared to those in the placebo-treated mice. Administration of propranolol increased cardiac performance in iron-overloaded mice. Specifically, as compared to the values in the iron-overloaded group, in iron-overloaded animals treated with propranolol left ventricular fractional shortening increased (from 31.6% to 44.2%, P =0.01) whereas left ventricular end-diastolic diameter decreased (from 4.1 ± 0.1 mm to 3.5 ± 0.1 mm, P =0.03). Propranolol did not alter cardiac systolic function or left ventricular sizes in the placebo group.


CONCLUSIONS
These results demonstrate that C57bl/6 mice are resistant to iron overload-induced myocardial injury and that treatment with propranolol is able to increase cardiac performance in iron-overloaded mice. However, since C57bl/6 mice were resistant to iron-induced injury, it remains to be evaluated further whether propranolol could prevent iron-overload cardiomyopathy.
Department of Pharmacology, National Institute of Health, Rome, Italy.
Marco
M
Musumeci
Sonia
S
Maccari
Paola
P
Sestili
Alessia
A
Massimi
Elisa
E
Corritore
Giuseppe
G
Marano
Liviana
L
Catalano
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D020746:Calcium Channels, L-Type / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D060467:Disease Resistance / Q000187:drug effects* / Q000235:genetics; D006397:Hematinics / Q000009:adverse effects / Q000494:pharmacology; D007501:Iron / Q000378:metabolism*; D019190:Iron Overload / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology*; D007505:Iron-Dextran Complex / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D051379:Mice; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D011433:Propranolol / Q000378:metabolism*; D013045:Species Specificity
D000319:Adrenergic beta-Antagonists; D020746:Calcium Channels, L-Type; D006397:Hematinics; D007505:Iron-Dextran Complex; D011433:Propranolol; D007501:Iron